. 2026 Jan 19;5(2):102542. doi: 10.1016/j.jacadv.2025.102542

Table 2.

Lipoprotein(a)-Associated ORs for Complexity and Extent of CAD

Analysis	Diagnosis of Obstructive CAD	P Value	Multivessel Disease	P Value	Intermediate or High SYNTAX-1 Score	P Value
Univariate
Lp(a) >230 nmol/L	1.89 (1.19-2.98)	0.006	2.33 (0.90-6.07)	0.083	2.85 (0.60-13.66)	0.190
Lp(a), per 100 nmol/L	1.19 (1.05-1.35)	0.008	1.34 (1.02-1.76)	0.036	1.24 (0.88-1.75)	0.218
Multivariable model^a
Lp(a) >230 nmol/L	2.01 (1.25-3.24)	0.004	2.75 (1.03-7.36)	0.045	3.11 (0.62-15.52)	0.167
Lp(a), per 100 nmol/L	1.24 (1.08-1.43)	0.002	1.44 (1.08-1.92)	0.013	1.31 (0.90-1.89)	0.155
Multivariable model^b
Lp(a) >230 nmol/L	1.86 (1.08-3.22)	0.026	2.38 (0.83-6.85)	0.108	1.88 (0.34-10.57)	0.472
Lp(a), per 100 nmol/L	1.22 (1.03-1.43)	0.018	1.43 (1.04-1.96)	0.028	1.28 (0.82-1.99)	0.279

Values are OR (95% CI). Obstructive CAD was defined as the presence of ≥50% stenosis in at least one coronary vessel with a diameter of ≥1.5 mm on invasive coronary angiography, or a history of percutaneous coronary intervention or coronary artery bypass grafting. Multivessel disease is defined as two- or three-vessel disease. Intermediate or high SYNTAX-1 is a score >22.

CAD = coronary artery disease; SYNTAX = the Synergy Between PCI with Taxus and Cardiac Surgery; other abbreviations as in Table 1.

Adjusted for age and sex.

Adjusted for age, sex, diabetes, hypertension, former smoking, total cholesterol (continuous), LDL-C (continuous), HDL-C (continuous), eGFR (continuous), and lipid-lowering therapy.